The 150 most important questions in cancer research and clinical oncology series: questions 86–93

Abstract

Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which spark diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 8 more questions are presented as follows. Question 86. In which circumstances is good supportive care associated with a survival advantage in patients with cancer? Question 87. Can we develop animal models to mimic immunotherapy response of cancer patients? Question 88. What are the mechanisms underlying hepatitis B virus-associated non-hepatocellular cancers? Question 89. Can we more precisely target tumor metabolism by identifying individual patients who would benefit from the treatment? Question 90. What type of cranial irradiation-based prophylactic therapy combination can dramatically improve the survival of patients with extensive small-cell lung cancer? Question 91. How can postoperative radiotherapy prolong overall survival of the patients with resected pIIIA-N2 non-small cell lung cancer? Question 92. What are the key molecular events that drive oral leukoplakia or erythroplakia into oral cancer? Question 93. How could we track the chemotherapeutics-driven evolution of tumor genome in non-small cell lung cancer for more effective treatment?

Tumor vasculature: a sally port for inhibiting cancer cell spreading

“…From these studies another interesting data set has emerged suggesting a possible switch from anaerobic to aerobic metabolism in non-angiogenic tumours. The possibility to target different aspects of the metabolic pathways supporting cancer cells is another emerging field of research [ 7 ] and its current status has been revived during the 2-day meeting. Finally, the importance of having more efficient mouse models for mechanistic and preclinical studies has been stressed and the recent innovations in this field have been additionally presented.…”

The 150 most important questions in cancer research and clinical oncology series: questions 94–101

“…With an objective to promote worldwide cancer research and even accelerate inter-countries collaborations, since the beginning of 2017, Cancer Communications (former title: Chinese Journal of Cancer ) has launched a program of publishing 150 most important questions in cancer research and clinical oncology [ 1 ]. We are providing a platform for researchers to freely voice-out their novel ideas, and propositions to enhance the communications on how and where our focus should be placed [ 2 – 13 ]. In this edition, 8 valuable and inspiring questions, Question 94–101, from highly distinguished professionals from different parts of the world are presented.…”

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

“…This may appear to be arduous research but with the help of artificial intelligence the process can be accelerated and standardized, and the benefits obtained could surpass the initial difficulties of translating laboratory findings into clinically applicable therapies. 14 Based on these, we may be able to enhance personalized cancer treatment, or at the very least, have a better understanding of the tumor, host, and microenvironment. For this, global data sharing would be an important milestone to attain.…”